OncLive TV

Prioty Islam, MD, MSc, discusses the importance of shared decision making between patients and clinicians when selecting among available BTK inhibitors in the treatment of chronic lymphocytic leukemia or mantle cell lymphoma.

Maxine Sun, PhD, MPH, discusses ongoing research efforts dedicated to examining the relationship between clonal hematopoiesis and cardiovascular disease in patients with renal cell carcinoma.

Guru P. Sonpavde, MD, discusses results from the phase 3 SWOG S1011 trial conducted in patients with muscle-invasive bladder cancer.

Yara Abdou, MD, discusses updates in the treatment of patients with HR-positive, HER2-negative breast cancer.

Mansoor Raza Mirza, MD, discusses the significance of the FDA approval of dostarlimab in combination with chemotherapy in patients with mismatch repair–deficient or microsatellite instability–high endometrial cancer.

Kathryn Hitchcock, MD, PhD, expands on potential clinical implications of the ongoing phase 3 ERAsur trial in metastatic colorectal cancer

David R. Wise, MD, PhD, discusses key trials establishing the benefit of hormone therapy– or chemotherapy-based doublet therapy for patients with metastatic hormone-sensitive prostate cancer

Kathleen N. Moore, MD, MS, discusses the investigation of ubamatamab alone or in combination with cemiplimab in patients with recurrent ovarian cancer.

Elizabeth Buchbinder, MD, discusses the rationale for investigating nivolumab maintenance therapy in patients with melanoma who experienced severe immune-related adverse effects due to combination therapy with nivolumab and ipilimumab, and details the findings of this investigation.

Masahiro Tsuboi, MD, discusses the updated survival results of the phase 3 ADAURA trial in resectable EGFR-mutant non–small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses potential combination strategies with KRAS G12C inhibitors in advanced non–small cell lung cancer.

Edgardo Santos, MD, FACP, FCCP, discusses testing and treatment in NRG1 fusion–positive non–small cell lung cancer.

Mohamad Mohty, MD, PhD, discusses unmet needs in patients with relapsed/refractory multiple myeloma and the rationale for investigating elranatamab monotherapy in this population in the phase 2 MagnetisMM-3 trial.

Nirav N. Shah, MD, discusses the background of the phase 1/2 BRUIN trial of pirtobrutinib in patients with heavily pretreated, relapsed/refractory mantle cell lymphoma.

Jan Bewersdorf, MD, discusses the design of an ongoing phase 1 trial investigating ruxolitinib plus abemaciclib in patients with primary or secondary myelofibrosis.

Whitfield B. Growdon, MD, expands on the FDA’s decision to withdraw the later-line indication of olaparib for patients with BRCA-mutated ovarian cancer.

Adrienne G. Waks, MD, discusses treatment alternatives in the third line and beyond for patients with metastatic HER2-positive breast cancer.

Solange Peters, MD, PhD, discusses current understandings of mechanisms of resistance to immunotherapy in non–small cell lung cancer.

Edward S. Kim, MD, MBA, discusses the importance of improving representation in clinical trials.

Paolo Tarantino, MD, discusses the evolution and impact of the continued investigation of antibody-drug conjugates in the treatment of patients with hormone receptor–positive breast cancer.

Susan Bal, MD, discusses questions remaining regarding sequencing of treatments in later lines for patients with relapsed/refractory multiple myeloma.

Seth Wander, MD, PhD, discusses challenges related to the ongoing platinum chemotherapy shortage for patients with breast cancer and other malignancies, as well as ways that oncologists and cancer centers can operate during the shortage to continue to provide appropriate care for patients.

Logan Roof, MD, discusses findings from a study investigating trends in lung cancer mortality across different sociodemographic populations and locations in the United States between 1999 and 2020.

Sarah Weiss, MD, discusses the ongoing phase 2/3 TEBE-AM trial of tebentafusp with or without pembrolizumab in a subset of pretreated patients with non-uveal melanoma.

Heather Han, MD, discusses initial safety and efficacy results from the phase 2 NATASHA trial in patients with early-stage HER2-positive breast cancer.

Ann M. Gillenwater, MD, discusses safety and efficacy data from the phase 1b/2 ASP-1929-181 trial evaluating the antibody-dye conjugate ASP-1929 in combination with pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.

Ulka Nitin Vaishampayan, MBBS, discusses toxicities associated with various treatment options for patients with renal cell carcinoma.

Sarah E. S. Leary, MD, MS, discusses findings from the phase 2 FIREFLY-1 trial in pediatric patients with low-grade glioma.

Neeraj Agarwal, MD, discusses future questions to be addressed following the phase 3 TALAPRO-2 trial evaluating the combination of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Pedro Barata, MD, MSc, discusses the relationship between the gut microbiome and treatment with immunotherapy in patients with renal cell carcinoma.